Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE
· Real-Time Price · USD
6.86
-0.10 (-1.44%)
At close: Jun 24, 2025, 3:59 PM
6.92
0.95%
After-hours: Jun 24, 2025, 06:09 PM EDT
-1.44% (1D)
| Bid | 6.55 |
| Market Cap | 1.06B |
| Revenue (ttm) | 104.94M |
| Net Income (ttm) | -112.33M |
| EPS (ttm) | -0.75 |
| PE Ratio (ttm) | -9.14 |
| Forward PE | -5.93 |
| Analyst | Buy |
| Ask | 7.22 |
| Volume | 949,206 |
| Avg. Volume (20D) | 1,467,941 |
| Open | 7.05 |
| Previous Close | 6.96 |
| Day's Range | 6.80 - 7.14 |
| 52-Week Range | 4.25 - 16.74 |
| Beta | -1.05 |
Analyst Forecast
According to 0 analyst ratings, the average rating for WVE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Wave Life Sciences Ltd. is scheduled to release its earnings on Aug 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-17.08%
Shares of vaccine and gene therapy stocks are trad...
Unlock content with
Pro Subscription
1 month ago
+7.47%
Wave Life Sciences shares are trading higher after Cantor Fitzgerald initiated coverage with an Overweight rating and $10 price target.
2 months ago · seekingalpha.com
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531Wave Life Sciences Ltd. release of multi-dose data from the phase 1b/2a open-label RestorAAtion-2 study, using WVE-006 for AATD-related lung disease, expected in 2025. Positive results were achieved i...
